VRCA
Verrica Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.30
−1.12%Year over year
Reported trailing growth
- Revenue
- +106.2%
- EBITDA
- +30.3%
- EBIT
- +27.4%
- EPS
- +79.0%
- Free cash flow
- +71.8%
- Operating cash flow
- +71.8%
Forward estimates
Based on analyst estimates
- Revenue
- +0.4%
- EBITDA
- -45.7%
- EPS
- -12.0%
Three-year CAGR
- Revenue
- +57.9%
- EBITDA
- +85.8%
- EBIT
- +81.9%
- Net income
- +76.6%
- EPS
- +88.6%
- Free cash flow
- +71.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026